Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.

The Journal of molecular diagnostics : JMD - 1 Jan 2013

Lade-Keller Johanne, Rømer Kirsten M, Guldberg Per, Riber-Hansen Rikke, Hansen Lise Lotte, Steiniche Torben, Hager Henrik, Kristensen Lasse S

Abstract excerpt

Patients diagnosed with BRAF V600E mutated cutaneous melanoma show response to treatment with the BRAF inhibitor Vemurafenib. Different methods for BRAF mutation detection exist; however, only the Cobas 4800 BRAF V600 Mutation Test has been approved by the US Food and Drug Administration for patient selection. The results from this test depend on the percentage of tumor cells in the samples, which clinically may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Formaldehyde
Share to Indoles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Melanoma

Share to Paraffin Embedding

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 23159593
DOI: 10.1016/j.jmoldx.2012.08.003

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.PMID 23159593Read ↗

Molecular platforms utilized to detect BRAF V600E mutation in melanoma.Semantic proximity Read ↗

Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma.Semantic proximity Read ↗

Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies.Semantic proximity Read ↗

Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.Semantic proximity Read ↗

A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma.Semantic proximity Read ↗

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.Semantic proximity Read ↗

Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.Semantic proximity Read ↗

Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.Semantic proximity Read ↗

Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection of BRAF V600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant MelanomaSemantic proximity Read ↗

Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.Semantic proximity Read ↗

Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.Semantic proximity Read ↗

Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.